The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a greater substantial decrease in body weight and benefit metabolic mar